Perospirone: Difference between revisions
CSV import |
CSV import |
||
| Line 28: | Line 28: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Perospirone.svg|Perospirone | |||
File:Perospirone-optimized-ball-and-stick.png|Perospirone | |||
</gallery> | |||
Latest revision as of 01:23, 20 February 2025
Perospirone is an atypical antipsychotic agent. It is a novel antipsychotic developed by Dainippon Sumitomo Pharma. It was approved for use in Japan in 2001. Perospirone has a high affinity for serotonin 5-HT2A receptors and dopamine D2 receptors. It also has an affinity for serotonin 5-HT1A receptors.
Etymology[edit]
The term "Perospirone" is derived from its chemical name, which is 4-[4-[4-(1-piperazinyl)-1-p-tolylbutyl]-2,6-difluorophenoxy]ethanol. The name is a combination of parts of its chemical structure and its pharmacological properties.
Pharmacology[edit]
Perospirone is classified as an atypical antipsychotic due to its unique pharmacological properties. It has a high affinity for serotonin 5-HT2A receptors and dopamine D2 receptors, which are thought to be involved in the pathophysiology of schizophrenia. Perospirone also has an affinity for serotonin 5-HT1A receptors, which may contribute to its antipsychotic and antidepressant effects.
Clinical Use[edit]
Perospirone is used in the treatment of schizophrenia. It is also used off-label for the treatment of bipolar disorder and as an adjunct in the treatment of major depressive disorder. The drug has been shown to be effective in reducing both positive and negative symptoms of schizophrenia.
Side Effects[edit]
Common side effects of perospirone include somnolence, akathisia, and hyperprolactinemia. Less common side effects include weight gain, orthostatic hypotension, and extrapyramidal symptoms. Rare but serious side effects include neuroleptic malignant syndrome and tardive dyskinesia.
